Objective-In aortic aneurysms the arterial vessel wall is dilated because of destruction of its integrity, which may lead to lethal vessel rupture. Chronic infiltration of inflammatory cells into the vessel wall is fundamental to aneurysm pathology. We aim to limit aneurysm growth by inhibition of inflammation and reducing endothelial cell (EC) activation with immunosuppressive drug azathioprine (Aza). Approach and Results-Aza and its metabolite 6-mercaptopurine have anti-inflammatory effects on leukocytes. We here demonstrate that treatment of ECs with 6-mercaptopurine inhibits cell activation as illustrated by reduced expression of interleukin-12, CCL5, CCL2, and vascular cell adhesion molecule-1 and inhibition of monocyte-EC adhesion. The underlying mechanism of 6-mercaptopurine involves suppression of GTPase Rac1 activation, resulting in reduced phosphorylation of c-Jun-terminal-N-kinase and c-Jun. Subsequently, the effect of Aza was investigated in aneurysm formation in the angiotensin II aneurysm mouse model in apolipoprotein E-deficient mice. We demonstrated that Aza decreases de novo aortic aneurysm formation from an average aneurysm severity score of 2.1 (control group) to 0.6 (Aza group), and that Aza effectively delays aorta pathology in a progression experiment, resulting in a reduced severity score from 2.8 to 1.7 in Aza-treated mice. In line with the in vitro observations, Aza-treated mice showed less c-Jun-terminal-N-kinase activation in ECs and reduced leukocyte influx in the aortic wall. 
A bdominal aortic aneurysm (AAA) formation is characterized by progressive degradation of the vessel wall, which may cause the formation of a balloon-like dilatation of the artery. Aneurysms are usually asymptomatic; however, these enlarged arteries are vulnerable to local rupture with high mortality rates. Because of decreased smoking habits in the Western society, the AAA incidence has declined recently from ≈5% to 2% of the elderly male population. 1 However, as the number of elderly people in Western society increases, AAA remains a serious health problem. In addition, a larger number of elderly people will be diagnosed by coincidence with a small aneurysm because of the use of more sophisticated imaging techniques. Small aneurysms are screened regularly on discovery to monitor the growth rate. When the size exceeds 5.5 cm, open or endovascular repair surgery is the only form of treatment. To date, commonly used medication, such as angiotensin-converting enzyme inhibitors, β-blockers, statins, and antibiotics, have been explored for treatment of AAA growth with variable success. [2] [3] [4] [5] [6] [7] Chronic inflammation of the aorta is fundamental in AAA pathology, with infiltrating leukocytes producing cytokines and proteases that cause progressive deterioration of the vessel wall. 8 Furthermore, analyses of gene expression profiles and various imaging techniques of murine aneurysm models underscored the role of inflammatory processes in AAA. [9] [10] [11] To date, many animal studies using anti-inflammatory drugs were successful in inhibition of initiation of aneurysm formation. For example, celecoxib, a nonsteroidal anti-inflammatory drug inhibiting cyclooxygenase-2, has been shown to prevent aneurysm formation potently in the mouse angiotensin II (AngII)-induced aneurysm model. 12 Multiple immunosuppressive drugs have been investigated in various aneurysm models. For example, sirolimus has been shown to prevent aneurysm formation in rats in the elastase model. 13 Furthermore, cyclosporine A has been described as a potent inhibitor of de novo aneurysm formation in mice, 14 whereas hydrocortisone causes increased aortic rupture and aneurysm formation in mice. 15 The inconclusive observations with immunosuppressive therapy to treat aneurysm progression in humans recently raised a relevant discussion. 16 It seemed obvious that anti-inflammatory therapy would be beneficial to stop aneurysm progression; however, it does not seem that simple in clinical practice. 16 Each immunosuppressive drug has its specific targets and underlying mechanism, which makes the impact of a specific drug on the vessel wall different, but maybe highly relevant to AAA progression. It should be emphasized that patients with AAA by definition already have an aneurysm at the moment when treatment is initiated, whereas most animal aneurysm experiments study prevention at the onset of aneurysm formation.
We propose that it is necessary to explore which antiinflammatory drugs affect the vessel wall directly in a beneficial way. Azathioprine (Aza) caught our attention because of its described beneficial effects on endothelial cells (ECs). Aza increases EC survival, 17 in contrast to sirolimus, which induces apoptosis, causing the thrombotic problems in sirolimus-coated coronary stents, 18 or cyclosporine A that is toxic to ECs and provokes vasculopathy. 19 We and others have previously shown that Aza maintains the contractile phenotype of smooth muscle cells 20, 21 and has an anti-inflammatory effect in macrophages 22 and T cells. 23 Thus, Aza seems a good candidate drug to treat inflammation and protect the vessel wall.
Here, we show that Aza and its active metabolite 6-MP potently modulate activation of small GTPase Rac1 and downstream c-Jun-terminal-N-kinase (JNK) in ECs. JNK is a kinase with a pivotal role in aneurysm pathology. 24 We demonstrate that the JNK activation status in ECs is also reduced in vivo during mouse aneurysm formation by Aza, and that Aza prevents aneurysm formation and inhibits aneurysm progression.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

6-MP Decreases EC Activation
To study the effect of Aza on proliferation and migration of ECs, the cells were treated with 6-MP, and subsequently serum-induced bromodeoxyuridine incorporation was measured or a migration assay was performed. Treatment of ECs with 6-MP did not result in changes in DNA synthesis ( Figure  IA in the online-only Data Supplement), and also the migratory capability in the scratch assay was not affected ( Figure IB in the online-only Data Supplement).
To investigate EC activation, we determined THP-1 monocyte adherence to quiescent and tumor necrosis factor-α (TNFα)-activated ECs in the presence or absence of 6-MP. Fluorescently labeled THP-1 cells predominantly adhered to TNFα-stimulated cells ( Figure 1A ). Pretreatment of either ECs or monocytes or both cell types with 6-MP resulted in reduced attachment of THP-1 cells.
Because treatment of just the ECs revealed reduced monocyte adherence, we analyzed the effect of low-dose 6-MP on the expression of several characteristic cytokines and adhesion molecules in ECs. ECs were pretreated overnight with or without 6-MP and then incubated with or without TNFα for 24 hours. TNFα significantly induced mRNA expression of Rantes (CCL5), monocyte chemoattractant protein-1 (CCL2), interleukin-12, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 ( Figure 1B ). 6-MP strongly inhibited expression of interleukin-12, CCL2, CCL5, and vascular cell adhesion molecule-1, whereas mRNA levels of intercellular adhesion molecule-1 were not changed.
Together these data demonstrate that 6-MP inhibits the inflammatory response of ECs selectively and reduced the adherence of monocytes, which is a crucial process in inflammatory diseases.
6-MP Inhibits Rac1 Activation and Rac1-Mediated Signaling
In activated CD4+ T lymphocytes, it has been established that the small GTPase Rac1 is a target of Aza/6-MP, which becomes permanently inactivated and thereby limits T-cell activation. 23, 25 Rac1 is a small G-coupled protein and member of the Rho family of GTPases involved in multiple cellular processes. We anticipated that the 6-MP-dependent disturbance of Rac1-mediated processes may not be limited to T cells. Therefore, we set out to determine the amount of activated Rac1 after 6-MP treatment in cultured ECs. In active Rac1 pulldown assays, the amount of GTP-bound Rac1 was increased on TNFα stimulation (Figure 2) . Moreover, the extent of Rac1 activation was decreased in the presence of 6-MP, both in unstimulated and in TNFα-activated ECs. As a control for TNFα activation, the amount of intercellular adhesion molecule-1 protein was assayed and shown to be equal under control and 6-MP conditions (Figure 2 ), similarly independent of 6-MP as on RNA expression levels ( Figure 1B) .
A proinflammatory pathway in ECs that is dependent on Rac1 activation involves JNK. 26 We show that in TNFα-stimulated ECs, 6-MP decreases the amount of JNK phosphorylation (p-JNK) and thus reduces JNK activation ( Figure 3A and 3B). A similar reduction in p-JNK was also observed when a Rac1 inhibitor was used, suggesting that indeed inactivation of Rac1 by 6-MP could be responsible for reduced levels of p-JNK.
Because JNK is an activator of the transcription factor partner c-Jun, a crucial component of the early response transcription factor activator protein-1, activation of c-Jun was determined. The amount of nuclear, active c-Jun was significantly abrogated in the presence of 6-MP or the Rac1 inhibitor ( Figure 3C ). These results suggest that proinflammatory responses in the presence of TNFα can be successfully dampened in ECs by 6-MP via inactivation of Rac1 ( Figure 3D ).
Azathioprine Reduces De Novo Aneurysm Formation
Inflammatory processes and JNK activation play key roles in aneurysm formation and both processes are inhibited by Aza; therefore, we studied the effect of Aza on aneurysm formation. First, a dose finding study was performed to determine the optimal oral Aza dose for mice. Chronic immunosuppression of humans is maintained at a dose of 1 to 4 mg Aza/kg per day. Therefore, apolipoprotein E-deficient mice were exposed to 10, 5, 1, and 0.1 mg Aza/kg per day, which was administered orally in a Western type diet. Circulating cell numbers were determined after 4 weeks of treatment, and we observed that only the low dose of 0.1 mg Aza/kg per day did not affect red blood cell counts and that these mice showed only limited reduction in white blood cell numbers ( Figure II in the onlineonly Data Supplement). Subsequent aneurysm experiments were performed with this low dose.
The effect of Aza on de novo aneurysm formation was investigated in the AngII infusion model, and the mice were treated with Aza from the onset of aneurysm induction. Three mice (3/14) died in the control group, whereas only 1 mouse (1/13) in the Aza-treated group died because of aortic rupture within the first week of the experiment. After 4 weeks, aortas were isolated and revealed that aneurysm formation is strongly inhibited by Aza because only 17% (2/12) of the Aza-treated mice develop an aneurysm ( Figure 4A ), whereas in the control group 73% (8/11) show aneurysm formation. Aneurysm severity is scored and mice in the control group show a more severe aortic phenotype with mostly type-III aneurysms, compared with the Aza-treated mice ( Figure 4B ), with predominantly healthy aortas. The type-III aneurysm score indicates that thoracic aneurysms are present in addition to AAA. Thoracic aneurysms of the descending aorta are clearly visible, whereas the so-called saccular aneurysms that develop in the ascending aorta ( Figure 4A , pink star; enlarged in Figure III in the online-only Data Supplement) are less obvious by macroscopic inspection, but can be identified by microscopic analyses of sections of aortic arches. All together, Aza strongly reduces the number and the severity of aneurysm formation from a total score of 2.1 to 0.6 ( Figure 4C ; P<0.01).
Azathioprine Reduces JNK Activation in ECs and Inhibits Inflammation
To confirm the immunosuppressive effect of Aza, we isolated draining lymph nodes of the thoracic aorta and compare expression levels of interferon-γ. Application of Aza indeed results in decreased mRNA expression of interferon-γ in lymph nodes, as well as decreased T-cell (CD3) and B-cell (CD19) content, which represents the reduced inflammatory status of the mouse on Aza treatment ( Figure IV in the onlineonly Data Supplement). To understand the protective effect of Aza on aneurysm formation, we aimed to study JNK activation and inflammation in the aortic vessel wall. 27 Only 2 aneurysms were formed in the Aza-treated mice, and taking into account that the cellular composition of aneurysms is extremely variable, we rationalized that analysis of the vessel wall within the aneurysm lesions may limit quantitative analyses. To circumvent this problem, we analyzed the descending thoracic aorta of all mice, which is a region of the aorta that did not show overt pathology (n=11 control and n=12 Aza-treated mice), yet systemic effects of AngII and Aza can be measured. p-JNK is low in medial smooth muscle cells in these sections. However, p-JNK is abundantly present in ECs on AngII infusion and significantly decreased by Aza in endothelium lining the lumen of the aorta segment ( Figure 4D ). On average 64% of the ECs show p-JNK in AngII-infused mice, whereas only 47% are p-JNK positive in the Aza-treated AngII mice (P<0.0004). Subsequently, the presence of leukocytes in the media and adventitia is determined and we observe decreased numbers of macrophages and T cells in the vessel wall of Aza-treated mice ( Figure 4E and 4F) . It is of importance to mention that in the AngII model, there is fibroblast hypertrophy, which causes thickening of the adventitia, which was not significantly different between control and Aza-treated aortas, with regard to the aortic ring sections that were quantified here (data not shown); therefore, the decreased inflammation on Aza was not just a reflection of adventitial area. In line with reduced leukocyte recruitment to the vessel wall, the expression of matrix metalloproteinase (MMP) 2 and MMP9 protein is also reduced after Aza treatment ( Figure V in the online-only Data Supplement). We conclude that Aza reduces endothelial JNK activation, recruitment of inflammatory cells to the aortic vessel wall, and attenuates protease expression.
Azathioprine Inhibits Aneurysm Progression
After demonstrating that Aza inhibits de novo aneurysm formation, we aimed to assess whether Aza also stabilizes the growth of existing aneurysms. In the AngII model, aortic dilation is already induced after 1 week. 28, 29 We started the Aza intervention 10 days after the onset of AngII infusion to allow initiation of aneurysm formation. In this experiment, all mice that died because of aortic rupture within the first 10 days (n=4 per group), before Aza treatment was initiated, were excluded from further analyses. One mouse in the control group was euthanized 1 day before harvest (day 30) because of immobility caused by aortic rupture (this mouse was typed as IV). Again, mice from the control group develop more severe aneurysms than the Aza-treated mice. According to the severity score, the most prevalent aneurysm types in the control group are types II and III, whereas Aza-treated mice develop predominantly type I and II aorta pathology ( Figure 5A and 5B). Aza attenuates the progression of aneurysm formation, resulting in a significantly lower severity score of 1.8 compared with 2.7 in controls ( Figure 5C ; P<0.02). The discrepancy between aneurysm incidence in the de novo and progression experiment is a feature of the AngII model, where incidence can vary between 50% and 100%. However, in our case, the de novo experiment was performed in mice that were bred in our facility for a year and in the progression experiment the mice were delivered from Charles River directly.
A similar pattern of p-JNK reduction is observed as in the de novo experiment. In the AngII-infused aortas, 62% of aortic ECs are positive for p-JNK in comparison with 47% in the delayed Aza-treated mice ( Figure 5D ; P<0.0001). Decreased EC activation is reflected by decreased inflammation in the vessel wall. In the control mice, 1 saccular aneurysm is detected in the outer wall of the ascending aorta ( Figure 5A , pink star). Macrophage influx in the media is damaging and, therefore, quantified to locally monitor the effect of Aza on inflammation in the vessel wall. Medial macrophage influx in the thoracic aorta has not been observed in early time points 29 ; however, we find it in 9 of 10 mice after 31 days of AngII infusion at this location. Interestingly, the Aza-treated mice show a strongly reduced macrophage influx into the media ( Figure 5E ), demonstrating the anti-inflammatory effect of Aza treatment, even when the onset of treatment was delayed in the disease process.
Azathioprine Inhibits Inflammation Within AAA
Although the pathology score of the entire aorta is decreased by Aza in the progression experiment, the effect of Aza within the AAA can be analyzed as well because all mice (n=10 per group) had developed an AAA. The outer (maximal) diameter is measured macroscopically ( Figure VIA in the onlineonly Data Supplement) and microscopically ( Figure 6A ) and is equal in control and Aza-treated mice, revealing that both methods are valid to determine aneurysm size. Also, the luminal maximal diameter is measured and did not differ significantly between the groups. In addition, the matrix components collagen ( Figure 6B ) and elastin ( Figure 6C ) colocalize mostly with the smooth muscle cell area ( Figure 6D Figure 6F ). p-JNK is abundantly present in different cell types within the AAA and overlapped, in part, with macrophage positive area (compare Figure 6E and 6F) . As a readout of the inflammatory state of the AAA, we analyzed proteases MMP2-and MMP9-positive area. Indeed, MMP2 and MMP9 area is significantly lower in the Aza-treated mice ( Figure VID and VIE in the online-only Data Supplement).
In conclusion, p-JNK is decreased in Aza-treated mice and may result in the decreased inflammatory status within these AAA. This site-specific decrease of p-JNK in the suprarenal aorta has been shown to be important to achieve improvement of aneurysm pathology. 30 
Discussion
In this study, we examined the effect of Aza on EC function and aneurysm development. Aza is a well-known immunosuppressive drug, yet not much is known about its cellular working mechanism. We reveal that 6-MP has an anti-inflammatory effect on endothelium, resulting in reduced monocyte adhesion. The underlying mechanism involves inhibition of Rac1, similarly as decreased Rac1-GTP levels have previously been observed in T cells treated with 6-MP. 23, 25 In ECs, active Rac1 is essential to activate signal transduction via JNK and subsequent activation of c-Jun, a constituent of the proinflammatory transcription factor activator protein-1. We show decreased Rac1 activation on 6-MP treatment in ECs and a strong reduction of p-JNK and c-Jun activation. Because the Rac1-JNK signaling pathway is one of the main proinflammatory pathways downstream of the AngII receptor type 1 and because JNK has been shown to play an important role in aneurysm development, 24 ,31-33 we performed aneurysm experiments using the AngII-mediated model. We demonstrate that Aza has a protective effect on de novo aneurysm formation in mice, where the incidence and aneurysm severity are reduced. Most meaningfully, Aza treatment inhibited aneurysm progression in mice and mediated its effect through inhibition of macrophage infiltration and reduced JNK activation in the vessel wall. In human surgical AAA and cerebral aneurysm material, JNK levels are strikingly elevated 24, 34 and even correlate with increased size and rupture risk in the latter, 35 suggesting that JNK inhibition could be a relevant target of intervention in the clinic. The protective effect of JNK inactivation can be explained by reducing the levels of the (active) proteases in the vessel wall and thus better preserved extracellular matrix. 24, 36 Along this line, we observe a reduction of MMP2 and MMP9 protein in the vessel wall and AAA of Aza-treated mice.
Furthermore, we show that the anti-inflammatory effect of 6-MP in ECs involves downregulation of expression of hallmark activation markers interleukin-12, CCL2/MCP1, CCL5/Rantes, and vascular cell adhesion molecule-1, which are involved in different steps of vascular inflammation. Cytokine interleukin-12 is secreted and can activate surrounding cells, chemokines CCL2 and CCL5 attract specific leukocytes, and vascular cell adhesion molecule-1 will capture leukocytes to penetrate the vessel wall, which are all downregulated by Aza. Chemokine CCL2 is one of the most prominent chemokines found in aneurysms, yet its function is inconsistent. In mice, MCP1 is important for the attraction of monocytes, which clearly aggravates aneurysm pathology, but it also plays a role in tissue repair, which alleviates aneurysm development. 9, 37, 38 Interestingly, the role of CCL5 is more apparent because recently, Iida et al 39 showed in 2 different AAA mouse models that inhibition of CCL5 prevented AAA development and progression. In addition, a polymorphism has been described for the receptor of CCL5 (CCR5 Δ32 deletion) that correlates with aneurysm formation in 2 of 3 human studies, [40] [41] [42] which suggests an active role for CCL5 in the human aneurysm. Attraction and penetration of macrophages to sites of activated aorta are key to achieve continuous aortic expansion from as early as 1 day after AngII infusion ≤56 days. 10, 29 The markedly reduced leukocyte influx that is observed after Aza treatment in both mouse aneurysm experiments involves reduced endothelial activation but may also partly be explained by a direct immunosuppressive effect of 6-MP on macrophages 22 and T cells. 23, 25 This may also explain our reduced p-JNK found in the AAA on Aza treatment. Because Rac1-mediated proinflammatory signaling cascades are not limited to ECs, macrophages, or T cells, it is likely that this pathway will also be inhibited by Aza in other cell types, including vascular smooth muscle cells and fibroblasts. Similarly, the effective chronic treatment of patients with inflammatory bowel disease with Aza 43-45 may involve Rac1 inhibition in inflammatory cells and in gut endothelial, smooth muscle, and epithelial cells. Other functions of Rac1, apart from JNK activation, will also be affected by Aza. In most cell types Rac1 stimulates actin polymerization resulting in rearrangement of the cytoskeleton that is necessary to change cell shape when migrating or for cell adhesion, 46 which we have not studied here. We think that the lack of success to translate anti-inflammatory drug regimes that are successful in mouse models to the clinic is, in part, because of the limited progression studies that have been performed in mice. An informative example is the antibiotic doxycycline that has been demonstrated to effectively prevent aneurysm development in multiple aortic aneurysm mouse models, [47] [48] [49] [50] beneficial effect of doxycycline therapy on aneurysm progression or repair. 51 This clinical observation is, however, in line with a recent progression study in mice, in which doxycycline did not show any effect on aneurysm progression, 52 suggesting that aneurysm initiation and progression involve more and different processes. The mouse JNK study by Yoshimura et al 24 does comprise a progression study in which JNK inhibitors indeed provoke aneurysm regression. Here, we performed an aneurysm prevention and progression study, which both show beneficial effects on aneurysm severity. Analysis of the AAA in our progression study reveals decreased inflammation and protease activity presumably because of the decreased level of p-JNK. Yet, no decrease in AAA size was observed. Probably, the timeframe of 3-week Aza treatment was too short to expect a significant effect, when comparing it with the 6-week treatment in the CaCl 2 aneurysm model by Yoshimura et al. 24 Obviously, aneurysm prevention is less difficult than inhibition of the growth of existing aneurysms, as can be observed in our AAA, whereas the challenge in humans is to cure existing aneurysms, involving vessel wall repair. In our view, the compound-specific impact of distinct anti-inflammatory drugs, not only on immune cells but also on endothelial and smooth muscle cells, has been overlooked and needs to be assessed. We demonstrate here that Aza reduces vascular inflammation, at least in part via an anti-inflammatory function in ECs, and thus inhibits aneurysm pathology. Although Aza has its side effects and may, therefore, not be the ideal drug for use in elderly patients with existing aneurysms, our data are highly relevant to eventually define the necessary characteristics of the ideal drug to control aneurysm growth in humans.
Abdominal aortic aneurysm (AAA) formation is characterized by progressive degradation of the vessel wall by inflammation. Apart from vascular repair surgery when the aorta diameter becomes large, there is no standardized pharmaceutical treatment available to stabilize AAA growth. A candidate drug to treat AAA should reduce inflammation without having a detrimental effect on the vascular cell types within the aorta wall. The study presented here reports on the anti-inflammatory function of immunosuppressive drug azathioprine on endothelial cells via inhibition of GTPase Rac1 and thereby reducing downstream Jun-terminal-N-kinase signaling. Azathioprine inhibited de novo AAA and progression of aneurysm development in the angiotensin II mouse model. We show that azathioprine has the capacity to decrease activation in other cell types than immune cells alone, which may explain its potency as anti-inflammatory drug in chronic inflammatory diseases of which AAA may be next.
Significance
